P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Crohn's and Colitis Année : 2024

P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID

A. Buisson
  • Fonction : Auteur
R. Altwegg
  • Fonction : Auteur
S. Nancey

Résumé

Background Several adalimumab preparations are now available on the market for patients with inflammatory bowel disease. Comparative satisfaction and tolerability are unknown. The aim of this study was to investigate inflammatory bowel disease patient satisfaction with approved adalimumab biosimilars and their originator. Methods In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with inflammatory bowel disease across 45 centres affiliated with the GETAID who completed a satisfaction questionnaire comprising four items each rated by a 10 points-scale. The differences in responses were performed using one-way analysis of variance followed by Tukey's Honest Significant Difference test. Results The most commonly used drugs at inclusion were Humira® (436/941, 46.3%), Amgevita® (177/941, 18.8%), and Hulio® (105/941, 11.2%). Mean overall satisfaction rate with adalimumab was 8.5 [standard deviation 1.8]. Overall satisfaction was significantly higher in patients treated with Humira® (8.6 [1.5]), Hulio® (8.6 [1.8]) or Amgevita® (8.5 [1.4]) < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma® (9.0 [1.4]), Humira® (8.9 [1.3]) and Hulio® (8.9 [1.7]) (< 0.05). A total of 299 patients (31.8%) described injection site reactions. Two hundred twenty-three patients (23.7%) reported that they were previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects. Conclusion In this real-world setting, patients with inflammatory bowel disease had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.

Dates et versions

hal-04584772 , version 1 (23-05-2024)

Identifiants

Citer

B. Caron, P. Seksik, A. Buisson, P. Wils, G. Savoye, et al.. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID. Journal of Crohn's and Colitis, 2024, 18 (Supplement_1), pp.i1925-i1925 Meeting Abstract P1071. ⟨10.1093/ecco-jcc/jjad212.1201⟩. ⟨hal-04584772⟩
45 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More